In this April 9, 2020 file photo, a chemist displays hydroxychloroquine tablets in New Delhi, India. U.S. regulators are revoking emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19. The Food and Drug Administration said Monday, June 15 that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. (AP Photo/Manish Swarup, File)
By Matthew Perrone
The U.S. Food and Drug Administration is revoking its emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19 amid growing evidence they don’t work and could cause deadly side effects.
The agency said Monday that the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. Citing reports of heart complications, the FDA said the drugs pose a greater risk to patients than any potential benefits.
The decades-old drugs, also prescribed for lupus and rheumatoid arthritis, can cause heart rhythm problems, severely low blood pressure, and muscle or nerve damage.
The move means that shipments of the drugs obtained by the federal government will no longer be distributed to state and local health authorities. The drugs are still available for alternate uses, so U.S. doctors could still prescribe them for COVID-19 — a practice known as off-label prescribing.
On Thursday, a National Institutes of Health expert panel revised its guidelines to specifically recommend against the drug’s use except in formal studies.
Trump aggressively pushed the drug beginning in the first weeks of the outbreak and stunned medical professionals when he revealed he took the drug preemptively against infection.
David McKillips, President and CEO of CEC Entertainment, discusses the ongoing Chuck E. Cheese brand refresh, new locations, updated play spaces and more.
Lila MacLellan, Senior Writer at Fortune, discusses how the healthcare industry is reacting to the murder of United Healthcare CEO Brian Thompson. Watch!
Matt Hougan from Bitwise Asset Management joins Cheddar to discuss how and why Bitcoin is continuing to rise and what the future holds for the cryptocurrency.
Should real estate agents fear AI? Tushar Garg CEO at Flyhomes says no. He joined Cheddar to discuss the future of AI in the Real Estate business and more.
Christopher Zara, Senior Editor at Fast Company joined Cheddar to discuss the newly formed "DOGE"’s new goal to cut 2-trillion dollars from federal spending.
Sharon Price John CEO and President at Build-A-Bear Workshop discusses leading the brand, new offerings, the status of Brick-and-Mortar experiences and more!